Serina Therapeutics (SER) Share-based Compensation (2018 - 2025)
Serina Therapeutics (SER) posted Share-based Compensation of -$2.8 million for Q4 2025, down 200.0% sequentially from $2.8 million in Q3 2025, and up 92.18% YoY from -$1.5 million in Q4 2024.
Serina Therapeutics (SER) Share-based Compensation (2018 - 2025) Analysis & Trends
Serina Therapeutics has reported Share-based Compensation for 8 years, with the latest figure at -$2.8 million in Q4 2025.
- Quarterly Share-based Compensation rose 92.18% year-over-year to -$2.8 million in Q4 2025, while the trailing twelve-month figure through Sep 2025 was -$33.6 million (down 145.82% YoY) and the FY2023 annual result came in at $68000.0, down 91.05% from the prior year.
- Share-based Compensation retreated to -$2.8 million in Q4 2025 per SER's latest filing, from $2.8 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $36.4 million in Q1 2024 and troughed at -$36.4 million in Q4 2024.
- A 5-year average of $2.1 million and a median of $188000.0 in 2021 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 1820100.0% in 2024, down 145516.0% in 2024.
- Over 5 years, Share-based Compensation stood at -$720000.0 in 2021, then soared by 115.83% to $114000.0 in 2022, then sank by 121.93% to -$25000.0 in 2023, then tumbled by 145516.0% to -$36.4 million in 2024, then soared by 92.18% to -$2.8 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered -$2.8 million, $2.8 million, and -$36.4 million for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Serina Therapeutics | 43.17 Mn | 20.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.85 Mn |
| Dec 31, 2025 | -2.85 Mn |
| Sep 30, 2025 | 2.85 Mn |
| Sep 30, 2025 | 2.85 Mn |
| Dec 31, 2024 | -36.40 Mn |
| Dec 31, 2024 | -36.40 Mn |
| Sep 30, 2024 | 36.40 Mn |
| Sep 30, 2024 | 36.40 Mn |
| Jun 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 458,000.00 |
| Mar 31, 2024 | 36.40 Mn |
| Mar 31, 2024 | 36.40 Mn |
| Dec 31, 2023 | -25,000.00 |
| Dec 31, 2023 | -25,000.00 |
| Sep 30, 2023 | 40,000.00 |
| Sep 30, 2023 | 40,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Mar 31, 2023 | 2,000.00 |